Journal of Biological Chemistry · 2004 · 104 citations · 31 references
Life SciencesCell BiologyPathologyCell ProliferationCell SignalingSignal TransductionCytokine Receptor SignalingGrowth Factor SignalingInflammatory SignalingLiver RegenerationMitogenic SignalingCell Proliferation StimulationEpidermal Growth Factor Receptor SignalingExtracellular Signal-regulated Kinase PathwayExtracellular Signal-regulated Kinase SignalingGrowth Factor Receptor ActivationHepatocyte Growth Factor Receptor SignalingHepatocyte ProliferationMitogenic Signal Transduction
Tumor necrosis factor (TNF) has multiple biological effects such as participating in inflammation, apoptosis, and cell proliferation, but the mechanisms of its effects on epithelial cell proliferation have not been examined in detail. At the early stages of liver regeneration, TNF functions as a priming agent for hepatocyte replication and increases the sensitivity of hepatocytes to growth factors such as transforming growth factor α (TGFα); however, the mechanisms by which TNF interacts with growth factors and enhances hepatocyte replication are not known. Using the AML-12 hepatocyte cell line, we show that TNF stimulates proliferation of these cells through transactivation of the epidermal growth factor receptor (EGFR). The transactivation mechanism involves the release of TGFα into the medium through activation of the metalloproteinase TNFα-converting enzyme (also known as ADAM 17). Binding of the ligand to EGFR initiates a mitogenic cascade through extracellular signal-regulated kinases 1 and 2 and the partial involvement of protein kinase B. TNF-induced release of TGFα and activation of EGFR signaling were inhibited by TNFα protease inhibitor-1, an agent that interferes with TNFα-converting enzyme activity. We suggest that TNF-induced transactivation of EGFR may provide an early signal for the entry of hepatocytes into the cell cycle and may integrate proliferative and survival pathways at the start of liver regeneration. Tumor necrosis factor (TNF) has multiple biological effects such as participating in inflammation, apoptosis, and cell proliferation, but the mechanisms of its effects on epithelial cell proliferation have not been examined in detail. At the early stages of liver regeneration, TNF functions as a priming agent for hepatocyte replication and increases the sensitivity of hepatocytes to growth factors such as transforming growth factor α (TGFα); however, the mechanisms by which TNF interacts with growth factors and enhances hepatocyte replication are not known. Using the AML-12 hepatocyte cell line, we show that TNF stimulates proliferation of these cells through transactivation of the epidermal growth factor receptor (EGFR). The transactivation mechanism involves the release of TGFα into the medium through activation of the metalloproteinase TNFα-converting enzyme (also known as ADAM 17). Binding of the ligand to EGFR initiates a mitogenic cascade through extracellular signal-regulated kinases 1 and 2 and the partial involvement of protein kinase B. TNF-induced release of TGFα and activation of EGFR signaling were inhibited by TNFα protease inhibitor-1, an agent that interferes with TNFα-converting enzyme activity. We suggest that TNF-induced transactivation of EGFR may provide an early signal for the entry of hepatocytes into the cell cycle and may integrate proliferative and survival pathways at the start of liver regeneration. Tumor necrosis factor (TNF) 1The abbreviations used are: TNF, tumor necrosis factor; TNFR, TNF receptor; TRADD, TNFR1-associated death domain protein; TRAF2, TNFR-associated factor; FADD, Fas-associated death domain; TGFα, transforming growth factor-α; EGFR, epidermal growth factor receptor; ADAM, a disintegrin and metalloproteinase; TACE, TNFα-converting enzyme; TAPI-1, TNFα protease inhibitor-1; DMEM, Dulbecco's modified Eagle's medium; MP, metalloproteinase; MMP, matrix MP; BrdUrd, bromodeoxyuridine; PBS, phosphate-buffered saline; ERK, extracellular signal-regulated kinase; MEK, mitogen-activated protein kinase/ERK kinase; HB-EGF, heparin-binding EGF-like growth factor; PI3K, phosphoinositide 3-kinase; PKB, protein kinase B (also known as Akt). is a pleiotropic cytokine that plays a role in diverse cellular responses such as inflammation, apoptosis, and proliferation. It binds to specific type 1 and type 2 receptors (TNFR1 and TNFR2), although TNFR1 is responsible for most of the biological effects of TNF. Binding of the ligand causes activation of the trimeric receptor and recruitment of adapter proteins that interact with specific domains of the receptor, most commonly the death domain (1Wallach D. Varfolomeev E.E. Malinin N.L. Goltsev Y.V. Kovalenko A.V. Boldin M.P. Annu. Rev. Immunol. 1999; 17: 331-367Crossref PubMed Scopus (1131) Google Scholar, 2MacEwan D.J. Cell. Signal. 2002; 14: 477-492Crossref PubMed Scopus (529) Google Scholar, 3Baud V. Karin M. Trends Cell Biol. 2001; 11: 372-377Abstract Full Text Full Text PDF PubMed Scopus (1381) Google Scholar). Specific TNF-induced responses require the association of different adapter proteins to the receptor. For example, the recruitment of adapter proteins such as TRADD and TRAF2 activates multiple signal transduction pathways, including the NFκB pathway, which can protect cells against apoptosis. In contrast, binding of the adapter protein FADD initiates a cascade of events that results in apoptosis. In the liver, signaling through TNFR1 induces cell survival, replication, or apoptosis, depending on the context (4Kirillova I. Chaisson M. Fausto N. Cell Growth & Differ. 1999; 10: 819-828PubMed Google Scholar, 5Pierce R.H. Campbell J.S. Stephenson A.B. Franklin C.C. Chaisson M. Poot M. Kavanagh T.J. Rabinovitch P.S. Fausto N. Am. J. Pathol. 2000; 157: 221-236Abstract Full Text Full Text PDF PubMed Scopus (106) Google Scholar, 6Xu Y. Bialik S. Jones B.E. Iimuro Y. Kitsis R.N. Srinivasan A. Brenner D.A. Czaja M.J. Am. J. Physiol. 1998; 275: C1058-C1066Crossref PubMed Google Scholar). We and others have shown that a lack of TNFR1 in knock-out mice inhibits liver regeneration after partial hepatectomy (7Yamada Y. Kirillova I. Peschon J.J. Fausto N. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 1441-1446Crossref PubMed Scopus (842) Google Scholar) and interferes with hepatic regeneration after acute chemical injury (8Yamada Y. Webber E.M. Kirillova I. Peschon J.J. Fausto N. Hepatology. 1998; 28: 959-970Crossref PubMed Scopus (216) Google Scholar, 9Chiu H. Gardner C.R. Dambach D.M. Durham S.K. Brittingham J.A. Laskin J.D. Laskin D.L. Toxicol. Appl. Pharmacol. 2003; 193: 218-227Crossref PubMed Scopus (70) Google Scholar). We also have shown that TNF functions as a priming agent that sensitizes hepatocytes to the effects of growth factors involved in liver regeneration. Furthermore, in normal liver, TNF synergistically enhances proliferation induced by growth factors TGFα and hepatocyte growth factor (10Webber E.M. Bruix J. Pierce R.H. Fausto N. Hepatology. 1998; 28: 1226-1234Crossref PubMed Scopus (241) Google Scholar). The mechanisms of the proliferative activity of TNF have not been elucidated, although it has been proposed that TNF modulates hepatocyte proliferation through TGFα (11Gallucci R.M. Simeonova P.P. Toriumi W. Luster M.I. J. Immunol. 2000; 164: 872-878Crossref PubMed Scopus (67) Google Scholar). The activation of TNFR1 signaling after partial hepatectomy, sequential activation of NFκB and signal transducer and activator 3 transcription factors, and increased interleukin-6 levels is necessary for hepatocyte replication (7Yamada Y. Kirillova I. Peschon J.J. Fausto N. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 1441-1446Crossref PubMed Scopus (842) Google Scholar, 12Cressman D.E. Greenbaum L.E. DeAngelis R.A. Ciliberto G. Furth E.E. Poli V. Taub R. Science. 1996; 274: 1379-1383Crossref PubMed Scopus (1325) Google Scholar). Nevertheless, the components of this pathway may act as cell survival factors and may not be directly involved in the triggering of hepatocyte replication (13Kovalovich K. Li W. DeAngelis R. Greenbaum L.E. Ciliberto G. Taub R. J. Biol. Chem. 2001; 276: 26605-26613Abstract Full Text Full Text PDF PubMed Scopus (243) Google Scholar, 14Blindenbacher A. Wang X. Langer I. Savino R. Terracciano L. Heim M.H. Hepatology. 2003; 38: 674-682Crossref PubMed Scopus (161) Google Scholar, 15Wallenius V. Wallenius K. Hisaoka M. Sandstedt J. Ohlsson C. Kopf M. Jansson J.O. Endocrinology. 2001; 142: 2953-2960Crossref PubMed Scopus (16) Google Scholar). If this is the case, the involvement of TNF in hepatocyte replication requires the activation of additional pathways that are directly linked to cell proliferation. We show here that the proliferative effect of TNF in AML-12 hepatocytes requires transactivation of the epidermal growth factor receptor (EGFR). Transactivation of EGFR by TNF is accomplished through the activity of TNFα-converting enzyme (TACE, also known as ADAM 17) a surface metalloproteinase that releases soluble TGFα from pro-TGFα anchored in the plasma membrane. Released TGFα binds to EGFR, activating a signaling cascade that leads to DNA replication. Materials—Materials were purchased from the following vendors: DMEM/F-12 medium, dexamethasone, and gentamicin from Invitrogen; an insulin:transferrin:selenium mixture from BD Biosciences; fetal bovine serum from Hyclone; recombinant mouse TNF and recombinant human TGFα from R & D Systems; U0126 and anti-rabbit horseradish peroxidase secondary antibody from Promega; AG1478, LY294002, GM6001, GM6001 negative control, MMP-9/MMP-13 inhibitor I, MMP-2/MMP-9 inhibitor II, MMP-8 inhibitor I, and MMP-3 inhibitor IV from Calbiochem; TAPI-1 from Peptides International (Louisville, KY); [3H]thymidine (25 Ci/mmol) and anti-mouse horseradish peroxidase secondary antibody from Amersham Biosciences; BrdUrd labeling reagent and anti-BrdUrd antibody from DAKO; ABC detection kit from Vectastain; ERK1/2 antibody as described previously (16Seger R. Seger D. Reszka A.A. Munar E.S. Eldar-Finkelman H. Dobrowolska G. Jensen A.M. Campbell J.S. Fischer E.H. Krebs E.G. J. Biol. Chem. 1994; 269: 25699-25709Abstract Full Text PDF PubMed Google Scholar); γ-[32P]ATP (3000 Ci/mmol) and Renaissance chemiluminescent reagent from PerkinElmer Life Sciences; Triton X-100, 3,3-diaminobenzidine tablets, phosphoamino acid standards, and protein A-Sepharose from Sigma; Immobilon P polyvinylidene difluoride membrane from Millipore; blotting grade dry milk from Bio-Rad; EGFR (immunoprecipitation) antibody from UBI; EGFR (Western blot) and PY99 antibodies from Santa Cruz Biotechnology; and TGFα-neutralizing antibody from R & D Systems. All other antibodies were purchased from Cell Signaling Technologies. Buffers—The buffers used were Triton lysis buffer (25 mm HEPES, pH 7.4, 5 mm EDTA, 5 mm EGTA, 150 mm NaCl, 10% glycerol, 1% Triton X-100, 50 mm NaF, 4 μg/ml aprotinin, 4 μg/ml leupeptin, 10 μg/ml 4-(2-aminoethyl)-benzenesulfonyl fluoride, 0.1% β-mercaptoethanol, 1 mm Na3VO4), an assay buffer (20 mm HEPES, pH 7.4, 20 mm MgCl2, 0.1% β-mercaptoethanol), and an assay buffer plus ATP (100 μm cold ATP, 20 μCi/ml ATP). Cell Culture—AML-12 hepatocytes, a cell line established from hepatocytes of a TGFα transgenic mouse, were cultured as described previously (17Wu J.C. Merlino G. Fausto N. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 674-678Crossref PubMed Scopus (250) Google Scholar). Unless otherwise indicated, cultures were grown to 60–70% confluence and then serum-starved overnight in complete medium containing no fetal bovine serum. When inhibitors were used, cells were pretreated for 30 min prior to stimulation with the indicated concentration of inhibitor, which remained in the medium for the remainder of the experiment. The final concentration of Me2SO, the diluent for the inhibitors, was present in the culture medium at 0.1% or less. When using the TGFα neutralizing antibody, cultures were preincubated with 3 μg/ml antibody for 2 h prior to stimulation. Aliquots of TNF and TGFα used for stimulation were also preincubated with antibody (3 μg/ml) for 2 h at room temperature. [3H]Thymidine Incorporation Assay—AML-12 cells were plated at 40,000 cells/well in culture and to overnight in 10% fetal bovine serum. The following the cells were with and complete medium containing no fetal bovine serum was to the The cells were the following for h otherwise [3H]Thymidine μCi/ml final was to the medium for the final 3 h of stimulation. The acid was from the and the was in and using a was in and the are as the with the the BrdUrd were plated in or and as described previously in the [3H]thymidine For the 3 h of the cultures were with BrdUrd labeling reagent at were and for 30 min at room with peroxidase was by in 1% in for 20 min at room temperature. were in and in at for min by in were then in anti-BrdUrd antibody at in containing 1% bovine serum for 1 h at and in were in anti-mouse secondary antibody at in PBS, 1% bovine serum for 30 min at room by were in ABC for 30 min at room and in 50 mm pH for 5 and then the 3,3-diaminobenzidine was in were for a of is indicated as a of Growth α were cultured and to [3H]thymidine Cell culture medium was h after stimulation and in at TGFα was by assay to the of for cell protein after the indicated cells in were with and by into of Triton lysis were for on the and then by at for 10 min at 4 were in at were following (20 were on and to Immobilon P polyvinylidene difluoride For 50 of was on Campbell J.S. J. Biol. Chem. 2001; 276: Full Text Full Text PDF PubMed Scopus Google Scholar) that were overnight at 4 were in 0.1% containing milk or bovine serum prior to with were then with with secondary antibody horseradish peroxidase at anti-mouse horseradish peroxidase at for 1 in and with a chemiluminescent Growth cells were in Triton lysis buffer containing no agent was overnight at 4 with 1 of antibody and 20 of a protein A-Sepharose The were with lysis buffer and with kinase The were then in buffer and on were to polyvinylidene difluoride overnight at 4 and then as described and of AML-12 cells were serum-starved overnight in medium containing the insulin:transferrin:selenium dexamethasone, and The medium was to and 1 of Life was to were for h and then as cell were as described EGFR was overnight of 2 of antibody, and protein were on and to to into the receptor. The were from the and by was from the and for phosphoamino acid as described previously Campbell J.S. J. Biol. Chem. 2001; 276: Full Text Full Text PDF PubMed Scopus Google Scholar). For phosphoamino acid were in 5 of 1 the and and 2 of were the of a 10 was in for min at room temperature. was in for were and with in and to for 5 min to were then to for of of Cell by Tumor the effects of TNF on cell replication, AML-12 cells were in medium for a that DNA replication as by BrdUrd labeling to a of serum-starved cells were to 20 TNF for h Cell labeling by BrdUrd increased to at h and to the as cultures by In TNF increased BrdUrd labeling by at h and also increased the cell by at h not AML-12 hepatocytes pro-TGFα (17Wu J.C. Merlino G. Fausto N. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 674-678Crossref PubMed Scopus (250) Google Scholar). Nevertheless, of TGFα to the culture medium enhances DNA replication At the used, TGFα increased BrdUrd labeling and h after and increased cell at that the EGFR is not with ligand and is to additional ligand stimulation. with this we that and also DNA replication in AML-12 cells at levels with with In contrast, interleukin-6 and to no effect not Tumor Cell Growth Growth have previously shown that TNF functions as a for cells and for hepatocytes in cultures but is effect in cultures (4Kirillova I. Chaisson M. Fausto N. Cell Growth & Differ. 1999; 10: 819-828PubMed Google Scholar). The that TNF functions as a complete for AML-12 hepatocytes in medium indicated that in these cells a proliferative signal may be by TNF. We that signaling from TGFα and EGFR is necessary for TNF stimulation of cell replication. this we examined the of TNF to DNA in cultures in which signaling from the ligand and its receptor was AML-12 cells were with TGFα-neutralizing antibody or with the EGFR inhibitor stimulation with TNF or TGFα for h the TGFα-neutralizing antibody the stimulation of DNA replication by TGFα and also DNA by that TGFα is for of the of proliferation in these of the cells to the TGFα-neutralizing antibody DNA The inhibitor inhibits EGFR kinase activity in the of the cultured cells to this inhibitor the of DNA replication by the of DNA replication by TNF or TGFα the results of the in 2 show that TNF-induced DNA replication requires TGFα and kinase activity from Tumor of Growth examined to TNF causes of EGFR cell from cultures with TNF or TGFα were with EGFR antibody and to that EGFR is on in AML-12 cells in medium as by using the antibody stimulation with TGFα increased The of TNF not a in the but it an in that the receptor be modified by after TNF stimulation. the specific in the EGFR that may be after to TNF or TGFα, we serum-starved cells with were to TNF or TGFα for min and for phosphoamino acid of TGFα and TNF increased EGFR by EGFR protein was then from the to which were after TNF and TGFα stimulation. an in and of the receptor but not Tumor DNA Signaling from Growth signaling pathway is by multiple kinase receptors and is involved in cell proliferation. ERK1/2 is for TNF-induced DNA replication in AML-12 we inhibited the ERK1/2 pathway by its activator with U0126 DNA replication induced by TNF or Growth factors and can also the phosphoinositide this pathway in TNF-induced DNA replication, we with the specific inhibitor DNA replication induced by TNF or TGFα was by this of ERK1/2 and in cells the in DNA replication but not cell The PI3K, and NFκB pathways are for survival proliferation after TNF to AML-12 EGFR signaling is for the activation of these pathways, we EGFR kinase activity with and for of PKB, and after TNF and TGFα stimulation. In we that the activation of PKB, and at and 5 min after TNF not 5 that of EGFR activity TNF stimulation the of ERK1/2 at and of at and and no effect on the of at effects on the activation of ERK1/2 and by TGFα, but this growth factor to We that activation of ERK1/2 by TNF is on EGFR activation of by TNF is on EGFR and activation of by TNF not EGFR signaling and through TNF Tumor the that TNF induces cell proliferation through the signaling pathway, the mechanisms responsible for this effect have not been is that is TNF receptors and The with TGFα neutralizing antibody shown in however, suggest that extracellular TGFα is for the TNF We EGFR be by TNF in a to the receptors and EGFR H. C. A. A. A. J. 1997; PubMed Scopus Google Scholar). In this case, EGFR transactivation requires the of EGFR by a with binding of the factor to We that TNF-induced proliferation of AML-12 cells requires the activity of a metalloproteinase that this we examined TNF the release of TGFα into the culture medium and inhibitors an effect on TGFα release and DNA replication in cells to TNF to TNF an in the of TGFα in the culture medium The inhibitor GM6001 this at of 10 and 50 an of GM6001 no effect The inhibitor also TNF-induced DNA replication by but no effect on DNA induced by that act in cell proliferation but not in EGFR activation by of may be involved in this we the effect of inhibitors with is a metalloproteinase disintegrin that proteins anchored in the cell membrane J. A. Annu. Rev. PubMed Scopus Google Scholar, R.A. Peschon J.J. Srinivasan S. N. N. M. R. 1997; PubMed Scopus Google Scholar). TNF, TGFα, and other of the can as for this enzyme T.J. M.J. R.A. A. N. Y. Acad. Sci. 2003; PubMed Scopus Google Scholar, M. J. J. J. J. 2003; PubMed Scopus Google Scholar). TAPI-1, a specific inhibitor of TACE, TNF-induced DNA replication and the release of TGFα into the medium a and In contrast, inhibitors of matrix and no effect on TNF-induced DNA replication activity is for TNF-induced serum-starved AML-12 cells were pretreated with of TAPI-1, or inhibitor for 30 were then or with 20 TNF TAPI-1 were and 50 and inhibitor concentration was 50 was from cultured AML-12 cells h after and TGFα levels were by assay as described serum-starved AML-12 cells were pretreated with of were then or with 20 TNF for DNA replication was by [3H]thymidine as described AML-12 cells were pretreated with 0.1% or the inhibitors were then or with 20 TNF for inhibitors were used at the following 50 5 and DNA replication was by [3H]thymidine as described are of at We shown to TNF-induced DNA replication, with EGFR with TAPI-1 or were with TNF or that TAPI-1 the of ERK1/2 induced by TNF and the of by TNF The inhibitor no effect on ERK1/2 or induced by suggest that TNF stimulates cell proliferation in AML-12 hepatocytes through the activation of TACE, which ligand in binds to EGFR to a mitogenic cascade that involves ERK1/2 and TNF induces multiple responses in the liver, including cytokine cell and cell proliferation N. J. 2000; Full Text PDF PubMed Google Scholar). the mechanisms by which TNF causes cytokine stimulation and have been is known the mechanisms by which TNF stimulates hepatocyte replication. of NFκB and signal transducer and activator 3 and increases in interleukin-6 are with hepatocyte proliferation in the liver in and in cell but it is these to cell survival or are in signaling events that in DNA replication. We have shown that TNF in with growth factors to hepatocyte replication (10Webber E.M. Bruix J. Pierce R.H. Fausto N. Hepatology. 1998; 28: 1226-1234Crossref PubMed Scopus (241) Google Scholar). is on the following TNF stimulation of hepatocyte replication in mouse in cell TNF stimulates hepatocyte DNA replication in cultures but has activity in cultures in medium, that it is not a complete and a of 10 of TNF enhances the proliferative activity of TGFα and hepatocyte growth factor in normal the TNF and mitogenic growth factors for hepatocytes, we examined the proliferative effects of TNF on AML-12 a hepatocyte cell line in this cells TGFα, which is anchored in the cell membrane. We show that in these cells TNF stimulates DNA replication by release of TGFα into the culture medium through the metalloproteinase disintegrin TGFα then activates EGFR and multiple signaling that are for DNA replication. The EGFR TGFα and are as J. A. Annu. Rev. PubMed Scopus Google Scholar). of these by releases soluble growth factors, a known as 2002; PubMed Scopus Google Scholar, M.H. 2002; 38: PubMed Scopus Google Scholar). The soluble factors from the to and EGFR of this type of mechanism EGFR transactivation by stimulation of receptors N. H. M. R. C. A. 1999; PubMed Scopus Google Scholar, A. G. N. Y. Acad. Sci. 2001; PubMed Scopus Google Scholar, Y. K. J. Cell Biol. 2002; PubMed Scopus Google Scholar) and EGFR transactivation in and cells J. Biol. Chem. 2002; Full Text Full Text PDF PubMed Scopus Google Scholar, Am. J. Physiol. 2001; PubMed Google Scholar). the mechanisms of EGFR signaling by ligand binding are is known the and of these of suggest that the cell surface known as ADAM and which a an role in of and EGFR T.J. M.J. R.A. A. N. Y. Acad. Sci. 2003; PubMed Scopus Google Scholar, K. J. Cell Sci. 2002; Google Scholar, A. S. Fischer A. J. 2003; PubMed Scopus Google Scholar, J. R.H. J. Biol. Chem. 2003; Full Text Full Text PDF PubMed Scopus Google Scholar). In has been in EGFR activation T.J. M.J. R.A. A. N. Y. Acad. Sci. 2003; PubMed Scopus Google Scholar, M. J. J. J. J. 2003; PubMed Scopus Google Scholar). In the described we show that activity is involved in TNF-induced TGFα and EGFR transactivation in AML-12 The inhibitor TAPI-1 interferes with TGFα release into the culture medium and EGFR signaling through ERK1/2 and PKB, DNA replication. of membrane proteins by at levels in cells but is by of cells to such as R.M. R.A. 2003; PubMed Scopus Google Scholar). We that in AML-12 hepatocytes TGFα is into the culture medium after TNF and that this release is by TAPI-1, that is by TNF. We not TNF activates TACE, but suggest that ERK1/2 may not be involved in ligand as has been proposed in other T.J. M.J. R.A. A. N. Y. Acad. Sci. 2003; PubMed Scopus Google Scholar, Y. J. J. Biol. Chem. 2002; Full Text Full Text PDF PubMed Scopus Google Scholar). Transactivation of EGFR by TNF has been described in the human K. J. S. J. 2002; PubMed Scopus Google epithelial cells L.E. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google and cells J. Biol. Chem. Full Text PDF PubMed Google but in EGFR transactivation involves the of EGFR, a mechanism that not in hepatocytes not At of it has also been shown that in the liver TNF may TGFα transcription (11Gallucci R.M. Simeonova P.P. Toriumi W. Luster M.I. J. Immunol. 2000; 164: 872-878Crossref PubMed Scopus (67) Google Scholar). results an of and growth factors in We suggest that in the liver, TNF the for cell survival through NFκB activation and also an for cell replication that involves the transactivation of EGFR through ligand At liver regeneration, of these is by mechanisms N. J. 2000; Full Text PDF PubMed Google Scholar). We and for and and for
31
A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
Roy A. Black, Charles T. Rauch, Carl J. Kozlosky et al. · Nature · 1997 · 3.1K citations
Yasuhiro Yamada, Jacques J. Peschon, Nelson Fausto · Proceedings of the National Academy of Sciences · 1997 · 942 citations · Full text